Berliner Schlaganfallregister - Nachbefragung Von Patienten Mit Schlaganfall
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 1,200
- Locations
- 1
- Primary Endpoint
- Primary efficacy endpoint: Number of patients who state that they received all the information they want about the causes and nature of their illness.
Study Overview
Brief Summary
The objective of this trial is to guarantee a follow-up of all stroke and transient ischemic attack (TIA) patients. With this follow-up assessment long term effects of therapy and prevention measures can be detected and monitored. It is part of quality assurance.
Detailed Description
Primary efficacy endpoint: Number of patients who state that they received all the information they want about the causes and nature of their illness Key secondary endpoint(s): Compliance/adherence with discharge medication. Re-events. Degree of Disability. Activities of daily living. Mortality.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •all patients eligible
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Primary efficacy endpoint: Number of patients who state that they received all the information they want about the causes and nature of their illness.
Time Frame: September 2010
Secondary Outcomes
- Compliance/adherence with discharge medication Activities of daily living(September 2010)
- Re-events(September 2010)
- Degree of Disability(September 2010)
- Mortality(September 2010)
